Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.
- 36-month sales agency agreement across three markets
- PSC Biotech to target regional, medium and large pharmaceutical manufacturers
- One APAS Independence instrument to be installed at BioTechnique in Pennsylvania
- CCS retains sale closure, pricing and recurring software and service revenue
- Instrument sales from the channel are expected from FY28 onwards
PSC Biotech Adds A New Pharmaceutical Sales Channel
Clever Culture Systems Ltd (ASX:CC5) is widening the commercial funnel for its APAS Independence automation platform through a 36-month sales agency agreement with PSC Biotech Corporation. The arrangement gives PSC Biotech exclusive agency status across pharmaceutical manufacturing in the United States, Canada and Singapore, targeting regional, medium and large manufacturers outside CCS’s current direct-sales focus.
The distinction matters. CCS will continue selling directly to strategically important global pharmaceutical accounts under its “Land and Expand” strategy, while PSC Biotech is intended to add a complementary channel rather than replace that effort. CCS said its technology is now being deployed or evaluated by eight of the world’s largest pharmaceutical companies, a base it describes as commercial validation for wider adoption.
Customer Reach Expands Without Surrendering Revenue Control
PSC Biotech will use its pharmaceutical relationships to identify and develop opportunities, then refer qualified leads to CCS. CCS retains responsibility for closing sales, setting instrument prices and collecting all ongoing software and service revenue. PSC Biotech will receive commissions on hardware sales from accepted referrals, with payment due 30 days after CCS receives payment from the customer.
That structure leaves the economics of the new channel only partly visible: the announcement does not disclose the commission rate, contract value, purchase price or any guaranteed sales. CCS says the partnership should generate a meaningful increase in qualified opportunities over the next 12 months, with instrument sales from those opportunities expected from FY28 onwards. The timing makes this a pipeline expansion story before it becomes a reported-revenue story.
Pennsylvania Centre To Showcase APAS Independence
PSC Biotech has committed to purchase one APAS Independence instrument within 90 days of signing for installation at its BioTechnique contract drug manufacturing facility in York, Pennsylvania. The instrument is expected to be qualified and validated for GMP use, creating a live manufacturing reference site for product demonstrations, customer evaluations and future showcases.
PSC Biotech brings more than 500 employees and a customer network of more than 1,000 organisations, according to CCS. The company also provides validation, engineering and regulatory consulting services, giving it a potential commercial interest beyond simply referring instrument leads. CCS’s existing pharmaceutical customer base had already reached eight in FY26, after the company reported a doubling of large pharmaceutical customers in its FY26 pharma expansion.
Conversion From Leads To Orders Is The Next Test
The agreement runs for an initial three years, with a possible 24-month extension by mutual agreement, although either party can terminate on three months’ written notice. CCS must also continue paying commissions on sales to agreed qualified leads completed within nine months of termination or expiry.
The immediate milestones are practical rather than financial: whether PSC Biotech places the committed order, how quickly the Pennsylvania centre is validated, and whether demonstrations convert into customer contracts. CCS and PSC Biotech’s chief executives are scheduled to discuss the partnership on 15 October, when the market may get more detail on the channel’s target customers and potential pipeline. Until then, the central question is whether PSC Biotech can turn its network into qualified opportunities at a pace that justifies the promised FY28 contribution.
Bottom Line?
The partnership broadens CCS’s addressable pharmaceutical sales reach, but its value will depend on conversion from referrals to signed instrument orders and recurring revenue.
Questions in the middle?
- When will PSC Biotech place and install the committed APAS Independence instrument at BioTechnique?
- How many qualified opportunities does PSC Biotech expect to generate over the next 12 months?
- What proportion of referred leads can convert into instrument sales from FY28 onward?